Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 30

1.

Does Once-Daily Raltegravir Have Any Role in the Antiretroviral Treatment?

Gutierrez-Valencia A, Chacón-Mora N, Ruiz-Valderas R, Ben-Marzouk-Hidalgo OJ, Torres-Cornejo A, Viciana P, Lopez-Cortes LF.

Medicine (Baltimore). 2015 Oct;94(43):e1743. doi: 10.1097/MD.0000000000001743.

2.

Higher Activation in CD4(+) T Cells But Similar Viral Control Among HIV/Hepatitis C Virus-Coinfected Patients on a Simplification Monotherapy.

BenMarzouk-Hidalgo OJ, Torres-Cornejo A, Gutierrez-Valencia A, Ruiz-Valderas R, Viciana P, López-Cortés LF.

AIDS Res Hum Retroviruses. 2016 Jan;32(1):6-11. doi: 10.1089/AID.2014.0299. Epub 2015 Oct 21.

PMID:
26414169
3.

Differential effects of viremia and microbial translocation on immune activation in HIV-infected patients throughout ritonavir-boosted darunavir monotherapy.

BenMarzouk-Hidalgo OJ, Torres-Cornejo A, Gutiérrez-Valencia A, Ruiz-Valderas R, Viciana P, López-Cortés LF.

Medicine (Baltimore). 2015 May;94(17):e781. doi: 10.1097/MD.0000000000000781.

4.

Telaprevir and ribavirin interaction: higher ribavirin levels are not only due to renal dysfunction during triple therapy.

Gutierrez-Valencia A, Ruiz-Valderas R, Ben-Marzouk-Hidalgo OJ, Torres-Cornejo A, Espinosa N, Castillo-Ferrando JR, Viciana P, Lopez-Cortes LF.

Antimicrob Agents Chemother. 2015;59(6):3257-62. doi: 10.1128/AAC.04795-14. Epub 2015 Mar 23.

5.

HCV viral decline at week 2 of Peg-IFN-alpha-2a/RBV therapy as a predictive tool for tailoring treatment in HIV/HCV genotype 1 co-infected patients.

Rivero-Juarez A, López-Cortés LF, Camacho A, Torres-Cornejo A, Gordon A, Ruiz-Valderas R, Torre-Cisneros J, Pineda JA, Viciana P, Rivero A.

PLoS One. 2014 Jun 19;9(6):e99468. doi: 10.1371/journal.pone.0099468. eCollection 2014.

6.

Low concordance and resistance mutation emergence in the HIV protease gene among circulating and cell-associated viruses at viral replication episodes during darunavir/ritonavir monotherapy.

Torres-Cornejo A, Benmarzouk-Hidalgo OJ, Gutierrez-Valencia A, Ruiz-Valderas R, Viciana P, López-Cortés LF.

HIV Med. 2015 Jan;16(1):57-61. doi: 10.1111/hiv.12170. Epub 2014 Jun 9.

7.

Impact of the peginterferon-α 2a and ribavirin plasma levels on viral kinetics and sustained virological response in genotype 1 HCV/HIV-co-infected patients with the unfavourable non-CC IL28B genotypes.

Torres-Cornejo A, Ruiz-Valderas R, Jimenez-Jimenez L, Abad-Molina C, Gutierrez-Valencia A, Viciana P, Lopez-Cortes LF.

J Viral Hepat. 2014 Mar;21(3):178-88. doi: 10.1111/jvh.12128. Epub 2013 Jul 17.

PMID:
24438679
8.

Darunavir minimum plasma concentration and ritonavir-boosted darunavir monotherapy outcome in HIV-infected patients.

Gutierrez-Valencia A, Torres-Cornejo A, BenMarzouk-Hidalgo OJ, Ruiz-Valderas R, Lluch A, Viciana P, López-Cortés LF.

Antivir Ther. 2014;19(5):443-7. doi: 10.3851/IMP2722. Epub 2014 Jan 16.

PMID:
24434370
9.

Immune activation throughout a boosted darunavir monotherapy simplification strategy.

BenMarzouk-Hidalgo OJ, Torres-Cornejo A, Gutiérrez-Valencia A, Ruiz-Valderas R, Viciana P, López-Cortés LF.

Clin Microbiol Infect. 2014 Dec;20(12):1297-303. doi: 10.1111/1469-0691.12521. Epub 2014 Feb 10.

10.

Cellular HIV reservoir replenishment is not affected by blip or intermittent viremia episodes during darunavir/ritonavir monotherapy.

Torres-Cornejo A, Benmarzouk-Hidalgo OJ, Gutiérrez-Valencia A, Pérez-Romero P, Martín-Peña R, Ruiz-Valderas R, Viciana P, Lopez-Cortes LF.

AIDS. 2014 Jan 14;28(2):201-8. doi: 10.1097/QAD.0000000000000060.

PMID:
24361681
11.

Role of ritonavir in the drug interactions between telaprevir and ritonavir-boosted atazanavir.

Gutierrez-Valencia A, Ruiz-Valderas R, Torres-Cornejo A, Viciana P, Espinosa N, Castillo-Ferrando JR, Lopez-Cortes LF.

Clin Infect Dis. 2014 Jan;58(2):268-73. doi: 10.1093/cid/cit693. Epub 2013 Oct 21.

PMID:
24145880
12.

The IL28B effect on hepatitis C virus kinetics among HIV patients after the first weeks of pegylated-interferon/ribavirin treatment varies according to hepatitis C virus-1 subtype.

Rivero-Juarez A, Lopez-Cortes LF, Camacho A, Caruz A, Torres-Cornejo A, Martinez-Dueñas L, Ruiz-Valderas R, Torre-Cisneros J, Gutierrez-Valencia A, Rivero A.

AIDS. 2013 Jul 31;27(12):1941-7. doi: 10.1097/QAD.0b013e328360ea1e.

PMID:
23917425
13.

Lopinavir plasma concentrations and virological outcome with lopinavir-ritonavir monotherapy in HIV-1-infected patients.

Lopez-Cortes LF, Ruiz-Valderas R, Sánchez-Rivas E, Lluch A, Gutierrez-Valencia A, Torres-Cornejo A, Benmarzouk-Hidalgo OJ, Viciana P.

Antimicrob Agents Chemother. 2013 Aug;57(8):3746-51. doi: 10.1128/AAC.00315-13. Epub 2013 May 28.

14.

Differences in HCV viral decline between low and standard-dose pegylated-interferon-alpha-2a with ribavirin in HIV/HCV genotype 3 patients.

Rivero-Juárez A, Lopez-Cortes LF, Camacho A, Torres-Cornejo A, Pineda JA, Marquez-Solero M, Caruz A, Ruiz-Valderas R, Torre-Cisneros J, Gutierrez-Valencia A, Rivero A.

PLoS One. 2012;7(11):e48959. doi: 10.1371/journal.pone.0048959. Epub 2012 Nov 8.

15.

Influence of IL28B polymorphisms on response to a lower-than-standard dose peg-IFN-α 2a for genotype 3 chronic hepatitis C in HIV-coinfected patients.

López-Cortés LF, Ruiz-Valderas R, Jimenez-Jimenez L, González-Escribano MF, Torres-Cornejo A, Mata R, Rivero A, Pineda JA, Marquez-Solero M, Viciana P; Grupo para el Estudio de las Hepatitis Víricas (HEPAVIR) de la Sociedad Andaluza de Enfermedades Infecciosas.

PLoS One. 2012;7(1):e28115. doi: 10.1371/journal.pone.0028115. Epub 2012 Jan 3.

16.

Intracellular and plasma pharmacokinetics of 400 mg of etravirine once daily versus 200 mg of etravirine twice daily in HIV-infected patients.

Gutiérrez-Valencia A, Martin-Peña R, Torres-Cornejo A, Ruiz-Valderas R, Castillo-Ferrando JR, López-Cortés LF.

J Antimicrob Chemother. 2012 Mar;67(3):681-4. doi: 10.1093/jac/dkr534. Epub 2011 Dec 21.

PMID:
22190606
17.

Efficacy of daptomycin versus vancomycin in an experimental model of foreign-body and systemic infection caused by biofilm producers and methicillin-resistant Staphylococcus epidermidis.

Domínguez-Herrera J, Docobo-Pérez F, López-Rojas R, Pichardo C, Ruiz-Valderas R, Lepe JA, Pachón J.

Antimicrob Agents Chemother. 2012 Feb;56(2):613-7. doi: 10.1128/AAC.05606-11. Epub 2011 Nov 28.

18.

Simplified human immunodeficiency virus maintenance therapy in virologically suppressed children with Ritonavir-boosted protease inhibitor monotherapy.

Neth O, Falcon-Neyra L, Ruiz-Valderas R, León Leal JA, Obando I, Alvarez Del Vayo Benito C, Lopez-Cortes LF.

Pediatr Infect Dis J. 2011 Oct;30(10):917. doi: 10.1097/INF.0b013e318223bc56. No abstract available.

PMID:
21915022
19.

Efficacy, safety and pharmacokinetic of once-daily boosted saquinavir (1500/100 mg) together with 2 nucleos(t)ide reverse transcriptase inhibitors in real life: a multicentre prospective study.

López-Cortés LF, Viciana P, Ruiz-Valderas R, Pasquau J, Ruiz J, Lozano F, Merino D, Vergara A, Terrón A, González L, Rivero A, Muñoz-Sanz A.

AIDS Res Ther. 2010 Mar 17;7:5. doi: 10.1186/1742-6405-7-5.

20.

Stepped-dose versus full-dose efavirenz for HIV infection and neuropsychiatric adverse events: a randomized trial.

Gutiérrez-Valencia A, Viciana P, Palacios R, Ruiz-Valderas R, Lozano F, Terrón A, Rivero A, López-Cortés LF; Sociedad Andaluza de Enfermedades Infecciosas.

Ann Intern Med. 2009 Aug 4;151(3):149-56. Epub 2009 Jul 6.

PMID:
19581631
21.

Role of pegylated interferon-alpha-2a and ribavirin concentrations in sustained viral response in HCV/HIV-coinfected patients.

Lopez-Cortes LF, Valera-Bestard B, Gutierrez-Valencia A, Ruiz-Valderas R, Jimenez L, Arizcorreta A, Terrón A, Viciana P.

Clin Pharmacol Ther. 2008 Nov;84(5):573-80. doi: 10.1038/clpt.2008.110. Epub 2008 Jul 2.

PMID:
18596682
22.

Efficacy of low-dose boosted saquinavir once daily plus nucleoside reverse transcriptase inhibitors in pregnant HIV-1-infected women with a therapeutic drug monitoring strategy.

Lopez-Cortes LF, Ruiz-Valderas R, Rivero A, Camacho A, Marquez-Solero M, Santos J, García-Lazaro M, Viciana P, Rodriguez-Baños J, Ocampo A.

Ther Drug Monit. 2007 Apr;29(2):171-6.

PMID:
17417070
23.

Clinical and pharmacokinetic data support once-daily low-dose boosted saquinavir (1,200 milligrams saquinavir with 100 milligrams ritonavir) in treatment-naive or limited protease inhibitor-experienced human immunodeficiency virus-infected patients.

Marin-Niebla A, Lopez-Cortes LF, Ruiz-Valderas R, Viciana P, Mata R, Gutierrez A, Pascual R, Rodriguez M.

Antimicrob Agents Chemother. 2007 Jun;51(6):2035-42. Epub 2007 Mar 19.

24.

Efavirenz trough levels are not associated with virological failure throughout therapy with 800 mg daily and a rifampicin-containing antituberculosis regimen.

Lopez-Cortes LF, Ruiz-Valderas R, Ruiz-Morales J, Leon E, de Campos AV, Marin-Niebla A, Marquez-Solero M, Lozano F, Valiente R.

J Antimicrob Chemother. 2006 Nov;58(5):1017-23. Epub 2006 Sep 6.

PMID:
16956905
25.

Therapeutic drug monitoring of efavirenz: trough levels cannot be estimated on the basis of earlier plasma determinations.

López-Cortés LF, Ruiz-Valderas R, Marín-Niebla A, Pascual-Carrasco R, Rodríguez-Díez M, Lucero-Muñoz MJ.

J Acquir Immune Defic Syndr. 2005 Aug 15;39(5):551-6.

PMID:
16044006
26.

Once-daily saquinavir-hgc plus low-dose ritonavir (1200/100 mg) in HIV-infected pregnant women: pharmacokinetics and efficacy.

López-Cortés LF, Ruiz-Valderas R, Pascual R, Rodriguez M, Marín Niebla A.

HIV Clin Trials. 2003 May-Jun;4(3):227-9. No abstract available.

PMID:
12815561
27.

Once-daily saquinavir-sgc plus low-dose ritonavir (1200/100 mg) in combination with efavirenz: pharmacokinetics and efficacy in HIV-infected patients with prior antiretroviral therapy.

López-Cortés LF, Ruiz-Valderas R, Viciana P, Mata R, Gómez-Vera J, Alarcón A, Pachón J.

J Acquir Immune Defic Syndr. 2003 Feb 1;32(2):240-2. No abstract available.

PMID:
12571537
28.

Pharmacokinetic interactions between efavirenz and rifampicin in HIV-infected patients with tuberculosis.

López-Cortés LF, Ruiz-Valderas R, Viciana P, Alarcón-González A, Gómez-Mateos J, León-Jimenez E, Sarasanacenta M, López-Pua Y, Pachón J.

Clin Pharmacokinet. 2002;41(9):681-90.

PMID:
12126459
29.

Intravitreal pharmacokinetics and retinal concentrations of ganciclovir and foscarnet after intravitreal administration in rabbits.

López-Cortés LF, Pastor-Ramos MT, Ruiz-Valderas R, Cordero E, Uceda-Montañés A, Claro-Cala CM, Lucero-Muñoz MJ.

Invest Ophthalmol Vis Sci. 2001 Apr;42(5):1024-8.

PMID:
11274081
30.

Intravitreal, retinal, and central nervous system foscarnet concentrations after rapid intravenous administration to rabbits.

López-Cortés LF, Ruiz-Valderas R, Lucero-Muñoz MJ, Cordero E, Pastor-Ramos MT, Marquez J.

Antimicrob Agents Chemother. 2000 Mar;44(3):756-9.

Supplemental Content

Loading ...
Support Center